Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Robert F. Struck"'
Autor:
Andrew H. Rodgers, William R. Waud, Lee Roy Morgan, Blaise W LeBlanc, Branko S. Jursic, Robert F. Struck
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The purpose of this investigation was to synthesize a series of carbonate and carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic metabolite of penclomedine (PEN) seen in patients. DM-PEN has been observed to
Autor:
Robert F. Struck, Stephen Boue, Richard B. Cole, Andrew H. Rodgers, Lee Roy Morgan, Blaise W LeBlanc, Chau-Wen Chou
Publikováno v:
International Journal of Mass Spectrometry. 231:147-155
Isophosphoramide mustard (IPM) is known to have substantial anti-cancer activities in various animal models. Liquid chromatography–electrospray mass spectrometry (LC–ES–MS) and LC–ES–MS/MS methodologies have been developed and applied to th
Autor:
Lee Roy Morgan, Andrew H. Rodgers, Gerard Bastian, Edmund Benes, William S. Waud, Christopher Papagiannis, Dan Krietlow, Branko S. Jursic, Robert F. Struck, Gerald LaHoste, Melissa Thornton, Melody Luttrell, Edward Stevens, Rodger Thompson
Publikováno v:
Tumors of the Central Nervous System-Primary and Secondary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94cc6804ae5f39982924d8e23adeb3b5
https://doi.org/10.5772/58353
https://doi.org/10.5772/58353
Autor:
Robert F. Struck, Steven Keir, Henry S. Friedman, William R. Waud, Lee Roy Morgan, Anita Tiwari
Publikováno v:
Cancer Chemotherapy and Pharmacology. 48:47-52
Purpose: The purpose of this investigation was to compare the antitumor activities of a series of acyl derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma metabolite of penclomedine (PEN) observed to be an active antitumor agent in vivo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 45:59-62
Purpose: The purpose of this investigation was to determine the base sequence specificity of isophosphoramide mustard (IPM), the alkylating metabolite of ifosfamide, by crosslinking of designed DNA oligomers in comparison with the clinical alkylating
Autor:
Anthony E. Pegg, Cynthia Kilborn, Robert F. Struck, Darell D. Bigner, Nancy S. Bullock, M. Eileen Dolan, Susan M. Ludeman, Paul Modrich, Henry S. Friedman, O. Michael Colvin, Robert C. Moschel, Stewart P. Johnson, Thomas P. Brent, Natalia A. Loktionova, Steve Keir, Qing Dong
Publikováno v:
Cancer Chemotherapy and Pharmacology. 43:80-85
Purpose: The human medulloblastoma cell line D283 Med (4-HCR), a line resistant to 4-hydroperoxycyclophosphamide (4-HC), displays enhanced␣repair of DNA interstrand crosslinks induced by phosphoramide mustard. D283 Med (4-HCR) cells are cross-resis
Autor:
Steven M. Schmid, Anita Tiwari, Joyce E. Harwell, William R. Waud, Robert C. Reynolds, Deborah G. Gordon, Robert F. Struck, Karen S. Gilbert, Beverly D. Garrett
Publikováno v:
ChemInform. 31
Seven new (2-chloroethyl)nitrosocarbamates have been synthesized as potential anticancer alkylating agents. These compounds were designed with carrier moieties that would either act as prodrugs or confer water solubility. All compounds were screened
Autor:
Nancy Mason-Liddil, J. G. Phillips, David S. Alberts, Denise J. Roe, Patricia M. Plezia, Robert F. Struck, Robert T. Dorr
Publikováno v:
JNCI Journal of the National Cancer Institute. 83:1739-1743
We previously reported that cimetidine but not ranitidine significantly enhances cyclophosphamide-induced bone marrow toxic effects and the appearance of cyclophosphamide alkylating species in a murine leukemia mouse model, and we advised caution in
Publikováno v:
Cancer Communications. 2:207-211
The cyclophosphamide metabolite, acrolein, was reacted with 2'-deoxyguanosine-3'-monophosphate, and two adducts were detected by high performance liquid chromatography and 32P-postlabeling assay. These adducts were resistant to dephosphorylation by n